<- Go Home
Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Market Cap
$6.0B
Volume
1.6M
Cash and Equivalents
$994.5M
EBITDA
-$486.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$30.16
52 Week Low
$13.52
Dividend
N/A
Price / Book Value
6.03
Price / Earnings
-10.91
Price / Tangible Book Value
6.03
Enterprise Value
$5.0B
Enterprise Value / EBITDA
-10.19
Operating Income
-$487.2M
Return on Equity
69.35%
Return on Assets
-41.33
Cash and Short Term Investments
$994.5M
Debt
N/A
Equity
$986.1M
Revenue
N/A
Unlevered FCF
-$260.6M
Sector
Biotechnology
Category
N/A